Key clinical point: Hypo-attenuated leaflet thickening (HALT) and reduced leaflet motion resulted in a minimal increase in valve gradients, which can be considered clinically insignificant.
Major finding: The incidence of HALT at 30 days was 13.3% in the TAVR group and 5% in the surgery group, a difference that reached statistical significance (P = .03). At 1 year, however, the difference did not differ significantly (27.5% vs. 20.2%, respectively; P = .19).
Study details: An analysis of 408 patients in the PARTNER 3 Low-Risk Computed Tomography Sub-study.
Disclosures: The trial was sponsored by Edwards Lifesciences. Dr. Makkar disclosed that he is a consultant for and has received research grants from Edwards Lifesciences, Abbott, Medtronic, and Boston Scientific. Dr. Mack is a consultant to Gore and an investigator for Abbott, Edwards Lifesciences, and Medtronic.
Makkar R et al. TCT 2019.